Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 31, 2009, Pages 12903-12908

  Ponzo, Marisa G ^a,b   Lesurf, Robert ^a,c   Petkiewicz, Stephanie ^a,b   O'Malley, Frances P ^d,e   Pinnaduwage, Dushanthi ^e   Andrulis, Irene L ^d,e   Bull, Shelley B ^e,f   Chughtai, Naila ^a   Zuo, Dongmei ^a   Souleimanova, Margarita ^a   Germain, David ^a   Omeroglu, Atilla ^b   Cardiff, Robert D ^g   Hallett, Michael ^a,c   Park, Morag ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epithelial to mesenchymal transition; Gene expression profiling; Mouse models

Indexed keywords

PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR SNAIL; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CONTROLLED STUDY; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BREAST TUMOR; EPITHELIUM; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; MESODERM; MORTALITY; MOUSE MAMMARY TUMOR ONCOVIRUS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MESODERM; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; TRANSCRIPTION FACTORS;

EID: 69149108735     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0810402106     Document Type: Article

References (30)

1. Sorlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874.
2. Da Silva L, Clarke C, Lakhani SR (2007) Demystifying basal-like breast carcinomas. J Clin Pathol 60(12):1328-1332.
3. Nielsen TO, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367-5374.
4. Livasy CA, et al. (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264-271.
5. Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86(11):2259-2265.
6. Lengyel E, et al. (2005) C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113(4):678-682.
7. Ghoussoub RA, et al. (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82(8):1513-1520.
8. Yamashita J, et al. (1994) Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54(7):1630-1633.
9. Taniguchi T, et al. (1995) Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1(9):1031-1034.
10. TakayamaH, et al. (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 94(2):701-706.
11. Liang TJ, Reid AE, Xavier R, Cardiff RD, Wang TC (1996) Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 97(12):2872-2877.
12. Jeffers M, et al. (1998) The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 95(24):14417-14422.
13. Gallego MI, Bierie B, Hennighausen L (2003) Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 22(52):8498-8508.
14. Abella JV, et al. (2005) Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 25(21):9632-9645.
15. Petkiewicz SL (2007) The Met receptor tyrosine kinase in mammary gland tumorigenesis and development. PhD Thesis (McGill University, Montreal).
16. Cardiff RD, Muller WJ (1993) Transgenic mouse models of mammary tumorigenesis. Cancer Surv 16:97-113.
17. Rosner A, et al. (2002) Pathway pathology: Histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 161(3):1087-1097.
18. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD (2007) EMT tumorigenesis in the mouse mammary gland. Lab Invest 87(12):1218-1226.
19. Herschkowitz JI, et al. (2007) Identification of conserved gene expression features between murine mammary carcinomamodels and human breast tumors. Genome Biol 8(5):R76.
20. Rakha EA, et al. (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495-506.
21. Finak G, et al. (2006) Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 8(5):R58.
22. Finak G, et al. (2008) Stromal gene expression predicts clinical outcome inbreast cancer. Nat Med 14(5):518-527.
23. Kaposi-Novak P, et al. (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116(6):1582-1595.
24. van de Vijver MJ, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009.
25. Andrulis IL, et al. (1998) neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 16(4):1340-1349.
26. Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL (2008) Prognostic effect of basal-like breast cancers is time dependent: Evidence from tissue microarray studies on a lymph node-negative cohort. Clin Cancer Res 14(13):4168-4174.
27. Welm AL, Kim S, Welm BE, Bishop JM (2005) MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci USA 102(12):4324-4329.
28. DiRenzo J, et al. (2002) Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 62(1):89-98.
29. Graveel CR, et al. (2009) Met induces diverse breast carcinomas in mice and is associated with human basal breast cancer 10.1073/pnas.0810403106.
30. Ursini-Siegel J, et al. (2008) ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 27(6):910-920.